Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Nephrology/Urology
Disease Category: Renal Cell Carcinoma
Trial Information
Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
The purpose of this study is to determine if either Sunitinib or Sorafenib can prevent recurrence of kidney cancer and to compare the effects (both good and bad) of the Sunitinib and the Sorafenib with Placebo (pills that look like the study drugs, but are inactive or do not contain the drug) on the patient and the patient's kidney cancer to see which is better.
Patient Inclusion Criteria:
- Renal (Kidney) cell carcinoma eligible for nephrectomy with curative intent
- Age > 18 years
- No prior cancers within 5 years
- No serious intercurrent illness
Patient Exclusion Criteria:
- Hypertension (elevated bldoo pressure) not controlled with medications
- HIV positive
Primary Outcomes: To demonstrate an improvement in disease-free survival in locally advanced renal cell carcinoma
Key Secondary Outcomes: To compare overall survival between the two regimens
Janeen V. Bazan, Oncology Research Nurse Program Coordinator
Sherman Health Systems
934 Center Street
Elgin, IL 60120
Phone: (847) 429-2907
Fax: (847) 429-3071
EMail: janeen.bazan@shermanhospital.org
View Google Map
Research Center Information: Sherman Health Systems
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
